Low Dose Oral Minoxdil in Androgenic Alopecia

In order to successfully treat androgenetic alopecia (AGA), this study compares the efficacy of low-dose oral minoxidil dosages of 0.25 mg and 1 mg. It addresses a critical gap in current research, as few studies have examined the relationship between low dosage and outcomes like hair diameter, density, patient satisfaction, and adverse effects, including hypertrichosis. Previous research suggests that low dose of oral minoxidil is a safe and well-tolerated option for hair loss, but the optimal dose for maximizing benefits while minimizing side effects remains unclear. This study aims to determine which dose offers the best balance of efficacy and safety for AGA patients.

NCT Number	NCT07018349
Lead Sponsor	Jinnah Postgraduate Medical Centre
Conditions	Androgenetic Alopecia (AGA)
Enrollment	76 participants
Start Date	2025-06-15
Primary Completion	2025-09-30 (estimated)
Study Completion	2025-10-20 (estimated)
Updated on ClinicalTrials.gov	2025-06-12